Roles of interleukin 17 in angiotensin II type 1 receptor-mediated insulin resistance

Hypertension

Volumn 59, Issue 2 SUPPL. 1, 2012, Pages 493-499

  Ohshima, Kousei ^a   Mogi, Masaki ^a   Jing, Fei ^a   Iwanami, Jun ^a   Tsukuda, Kana ^a   Min, Li Juan ^a   Higaki, Jitsuo ^a   Horiuchi, Masatsugu ^a  

^a EHIME UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

angiotensin II type 1 receptor blocker; insulin resistance; interleukin 17; low grade inflammation

Indexed keywords

ADIPONECTIN; ANGIOTENSIN 1 RECEPTOR; DEOXYGLUCOSE; HYDRALAZINE; IMMUNOGLOBULIN G2A; INTERLEUKIN 17; INTERLEUKIN 17 ANTIBODY; TELMISARTAN; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANTIIDIOTYPIC ANTIBODY; BENZIMIDAZOLE DERIVATIVE; BENZOIC ACID DERIVATIVE; GLUCOSE; INSULIN; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; CONFERENCE PAPER; CONTROLLED STUDY; INSULIN RESISTANCE; INSULIN TOLERANCE TEST; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; ORAL GLUCOSE TOLERANCE TEST; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; ANIMAL; ARTICLE; C57BL MOUSE; DISEASE MODEL; DRUG EFFECT; IMMUNOLOGY; MALE; METABOLISM; PATHOPHYSIOLOGY; PHYSIOLOGY; SKELETAL MUSCLE; ADIPOCYTE; CELL DIFFERENTIATION; CONCENTRATION (PARAMETERS); PROTEIN PHOSPHORYLATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANIMALS; ANTIBODIES, ANTI-IDIOTYPIC; BENZIMIDAZOLES; BENZOATES; DIABETES MELLITUS, TYPE 2; DISEASE MODELS, ANIMAL; GLUCOSE; INSULIN RESISTANCE; INTERLEUKIN-17; MALE; MICE; MICE, INBRED C57BL; MUSCLE, SKELETAL; RECEPTOR, ANGIOTENSIN, TYPE 1;

EID: 84856104448     PISSN: 0194911X     EISSN: 15244563     Source Type: Journal    
DOI: 10.1161/HYPERTENSIONAHA.111.183178     Document Type: Conference Paper

References (39)

1. Shoelson SE, Lee J, Goldfine AB. Inflammation and insulin resistance. J Clin Invest. 2006;116:1793-1801. (Pubitemid 44033299)
2. de Luca C, Olefsky JM. Inflammation and insulin resistance. FEBS Lett. 2008;582:97-105. (Pubitemid 50010731)
3. Donath MY, Shoelson SE. Type 2 diabetes as an inflammatory disease. Nat Rev Immunol. 2011;11:98-107.
4. Hotamisligil GS, Spiegelman BM. Tumor necrosis factorα: A key component of the obesity-diabetes link. Diabetes. 1994;43:1271-1278.
5. Hotamisligil GS, Arner P, Caro JF, Atkinson RL, Spiegelman BM. Increased adipose tissue expression of tumor necrosis factor-α in human obesity and insulin resistance. J Clin Invest. 1995;95:2409-2415.
6. Sartipy P, Loskutoff DJ. Monocyte chemoattractant protein 1 in obesity and insulin resistance. Proc Natl Acad Sci U S A. 2003;100:7265-7270. (Pubitemid 36706427)
7. Pradhan AD, Manson JE, Rifai N, Buring JE, Ridker PM. C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA. 2001;286:327-334. (Pubitemid 32656163)
8. Spranger J, Kroke A, Mohlig M, Hoffmann K, Bergmann MM, Ristow M, Boeing H, Pfeiffer AF. Inflammatory cytokines and the risk to develop type 2 diabetes: Results of the prospective population-based European Prospective Investigation Into Cancer and Nutrition (EPIC)-Potsdam Study. Diabetes. 2003;52:812-817. (Pubitemid 36323590)
9. Perkins JM, Davis SN. The renin-angiotensin-aldosterone system: A pivotal role in insulin sensitivity and glycemic control. Curr Opin Endocrinol Diabetes Obes. 2008;15:147-152. (Pubitemid 351674095)
10. Olivares-Reyes JA, Arellano-Plancarte A, Castillo-Hernandez JR. Angiotensin II and the development of insulin resistance: Implications for diabetes. Mol Cell Endocrinol. 2009;302:128-139.
11. Shiuchi T, Iwai M, Li HS, Wu L, Min LJ, Li JM, Okumura M, Cui TX, Horiuchi M. Angiotensin II type-1 receptor blocker valsartan enhances insulin sensitivity in skeletal muscles of diabetic mice. Hypertension. 2004;43:1003-1010. (Pubitemid 38579905)
12. Cheng X, Yu X, Ding YJ, Fu QQ, Xie JJ, Tang TT, Yao R, Chen Y, Liao YH. The Th17/Treg imbalance in patients with acute coronary syndrome. Clin Immunol. 2008;127:89-97.
13. Eid RE, Rao DA, Zhou J, Lo SF, Ranjbaran H, Gallo A, Sokol SI, Pfau S, Pober JS, Tellides G. Interleukin-17 and interferon-α are produced concomitantly by human coronary artery-infiltrating T cells and act synergistically on vascular smooth muscle cells. Circulation. 2009;119: 1424-1432.
14. Smith E, Prasad KM, Butcher M, Dobrian A, Kolls JK, Ley K, Galkina E. Blockade of interleukin-17a results in reduced atherosclerosis in apolipoprotein E-deficient mice. Circulation. 2010;121:1746-1755.
15. Zuniga LA, Shen WJ, Joyce-Shaikh B, Pyatnova EA, Richards AG, Thom C, Andrade SM, Cua DJ, Kraemer FB, Butcher EC. IL-17 regulates adipogenesis, glucose homeostasis, and obesity. J Immunol. 2010;185: 6947-6959.
16. Aggarwal S, Gurney AL. IL-17: Prototype member of an emerging cytokine family. J Leukoc Biol. 2002;71:1-8. (Pubitemid 34062767)
17. Madhur MS, Lob HE, McCann LA, Iwakura Y, Blinder Y, Guzik TJ, Harrison DG. Interleukin 17 promotes angiotensin II-induced hypertension and vascular dysfunction. Hypertension. 2010;55:500-507.
18. Nishimura M. Breeding of mice strains for diabetes mellitus. Exp Anim. 1969;18:147-157.
19. Emamaullee JA, Davis J, Merani S, Toso C, Elliott JF, Thiesen A, Shapiro AM. Inhibition of Th17 cells regulates autoimmune diabetes in nod mice. Diabetes. 2009;58:1302-1311.
20. de Latour RP, Visconte V, Takaku T, Wu C, Erie AJ, Sarcon AK, Desierto MJ, Scheinberg P, Keyvanfar K, Nunez O, Chen J, Young NS. Th17 immune responses contribute to the pathophysiology of aplastic anemia. Blood. 2010;116:4175-4184.
21. Krege JH, Hodgin JB, Hagaman JR, Smithies O. A noninvasive computerized tail-cuff system for measuring blood pressure in mice. Hypertension. 1995;25:1111-1115.
22. Sakata A, Mogi M, Iwanami J, Tsukuda K, Min LJ, Jing F, Iwai M, Ito M, Horiuchi M. Female exhibited severe cognitive impairment in type 2 diabetes mellitus mice. Life Sci. 2010;86:638-645.
23. Shiuchi T, Nakagami H, Iwai M, Takeda Y, Cui T, Chen R, Minokoshi Y, Horiuchi M. Involvement of bradykinin and nitric oxide in leptinmediated glucose uptake in skeletal muscle. Endocrinology. 2001;142: 608-612. (Pubitemid 32222409)
24. Sudo M, Minokoshi Y, Shimazu T. Ventromedial hypothalamic stimulation enhances peripheral glucose uptake in anesthetized rats. Am J Physiol. 1991;261:E298-E303.
25. Min LJ, Mogi M, Li JM, Iwanami J, Iwai M, Horiuchi M. Aldosterone and angiotensin II synergistically induce mitogenic response in vascular smooth muscle cells. Circ Res. 2005;97:434-442. (Pubitemid 41298173)
26. Ohashi K, Kihara S, Ouchi N, Kumada M, Fujita K, Hiuge A, Hibuse T, Ryo M, Nishizawa H, Maeda N, Maeda K, Shibata R, Walsh K, Funahashi T, Shimomura I. Adiponectin replenishment ameliorates obesity-related hypertension. Hypertension. 2006;47:1108-1116. (Pubitemid 44289168)
27. Hotamisligil GS, Shargill NS, Spiegelman BM. Adipose expression of tumor necrosis factor-α: Direct role in obesity-linked insulin resistance. Science. 1993;259:87-91. (Pubitemid 23036092)
28. Morimoto Y, Nishikawa K, Ohashi M. Kb-r7785, a novel matrix metalloproteinase inhibitor, exerts its antidiabetic effect by inhibiting tumor necrosis factor-α production. Life Sci. 1997;61:795-803. (Pubitemid 27326935)
29. Sumarac-Dumanovic M, Stevanovic D, Ljubic A, Jorga J, Simic M, Stamenkovic-Pejkovic D, Starcevic V, Trajkovic V, Micic D. Increased activity of interleukin-23/interleukin-17 proinflammatory axis in obese women. Int J Obes (Lond). 2009;33:151-156.
30. Winer S, Paltser G, Chan Y, Tsui H, Engleman E, Winer D, Dosch HM. Obesity predisposes to Th17 bias. Eur J Immunol. 2009;39:2629-2635.
31. Jagannathan-Bogdan M, McDonnell ME, Shin H, Rehman Q, Hasturk H, Apovian CM, Nikolajczyk BS. Elevated proinflammatory cytokine production by a skewed T cell compartment requires monocytes and promotes inflammation in type 2 diabetes. J Immunol. 2011;186: 1162-1172.
32. Kurtz TW. Beyond the classic angiotensin-receptor-blocker profile. Nat Clin Pract Cardiovasc Med. 2008;5(suppl 1):S19-S26. (Pubitemid 351940520)
33. Cawthorn WP, Heyd F, Hegyi K, Sethi JK. Tumour necrosis factor-α inhibits adipogenesis via aβ-catenin/TCF4(TCF7L2)-dependent pathway. Cell Death Differ. 2007;14:1361-1373. (Pubitemid 46965265)
34. Hotamisligil GS, Peraldi P, Budavari A, Ellis R, White MF, Spiegelman BM. IRS-1-mediated inhibition of insulin receptor tyrosine kinase activity in TNF-α - and obesity-induced insulin resistance. Science. 1996;271: 665-668. (Pubitemid 26052915)
35. Platten M, Youssef S, Hur EM, Ho PP, Han MH, Lanz TV, Phillips LK, Goldstein MJ, Bhat R, Raine CS, Sobel RA, Steinman L. Blocking angiotensin-converting enzyme induces potent regulatory T cells and modulates Th1- and Th17-mediated autoimmunity. Proc Natl Acad Sci U S A. 2009;106:14948-14953.
36. Itoh M, Suganami T, Hachiya R, Ogawa Y. Adipose tissue remodeling as homeostatic inflammation. Int J Inflam. 2011;2011:720926.
37. Rahmouni K, Mark AL, Haynes WG, Sigmund CD. Adipose depotspecific modulation of angiotensinogen gene expression in diet-induced obesity. Am J Physiol Endocrinol Metab. 2004;286:E891-E895. (Pubitemid 38668809)
38. Van Harmelen V, Ariapart P, Hoffstedt J, Lundkvist I, Bringman S, Arner P. Increased adipose angiotensinogen gene expression in human obesity. Obes Res. 2000;8:337-341.
39. Engeli S, Bohnke J, Gorzelniak K, Janke J, Schling P, Bader M, Luft FC, Sharma AM. Weight loss and the renin-angiotensin-aldosterone system. Hypertension. 2005;45:356-362. (Pubitemid 40315803)